These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
Sarepta Therapeutics (NASDAQ: SRPT) and Amicus Therapeutics (NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may still want to add them to their portfolios despite their sky-high valuations. Both companies already market fast-growing, FDA-approved drugs and each is developing new drugs for rare diseases that could significantly expand their peak sales opportunity.
Sarepta Therapeutics markets Exondys 51, an exon-skipping drug that helps restore dystrophin production in about 13% of Duchenne's muscular dystrophy (DMD) patients.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Sarepta Therapeutics Stock
€110.05
0.310%
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 18.13% for Sarepta Therapeutics compared to the current price of 110.05 €.
